BofA Securities on BioCryst Pharma (BCRX) 'Stock’s weakness offers particularly attractive entry point'
(Updated - November 4, 2024 2:16 PM EST)
BofA Securities analyst Tazeem Ahmad reiterated a Buy rating and $11.00 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
BofA Securities analyst Tazeem Ahmad reiterated a Buy rating and $11.00 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)